Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

37.05
+0.46261.26%
Volume:2K
Turnover:63.65K
Market Cap:91.51M
PE:- -
High:37.24
Open:37.02
Low:37.02
Close:36.59
52wk High:39.48
52wk Low:32.44
Shares:2.47M
Float Shares:2.47M
Volume Ratio:1.52
T/O Rate:0.07%
Dividend:0.33
Dividend Rate:0.89%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

AcroMeta Moves Into Cell Therapy Logistics With Southeast Asia ATCLS Deal

TIPRANKS
·
Sep 05

Lilly Targets Type 1 Diabetes With New Tirzepatide Study: What Investors Should Watch

TIPRANKS
·
Sep 05

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

TIPRANKS
·
Sep 04

J.P. Morgan Remains a Buy on Ventas (VTR)

TIPRANKS
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

Guizhou-Based Firm Earns National Recognition for Veterans Support Efforts

Deep News
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03